Ceregene
Ceregene is a privately held San Diego-based biotechnology company founded in 2000 that develops therapies for neurodegenerative disorders by delivering nervous system growth factors to the nervous system.
- Company typePrivate
- Founded2000
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Ceregene does
Ceregene is a privately held biotechnology company founded in 2000 and headquartered in San Diego, California. The company focuses on treating neurodegenerative disorders through the delivery of nervous system growth factors, a therapeutic modality consistent with gene-therapy-based approaches to central nervous system diseases. Its intended end beneficiaries are patients with neurodegenerative conditions such as Parkinson's disease, Alzheimer's disease, and related disorders, and its customers in the near term are research collaborators, clinical investigators, and the foundations that fund CNS drug development rather than commercial payers.
The company's core technology centers on delivering growth factors to the nervous system — a platform approach that requires sophisticated biologics, viral vector, and clinical development expertise. Based on its disclosed funding profile, Ceregene has operated as a venture-backed, R&D-intensive biotech, accumulating approximately $71.5 million across three identified financing rounds between 2004 and 2010. Its investor base spans dedicated life-sciences venture firms (Alta Partners, MPM Capital, Hamilton BioVentures, California Technology Ventures, Investor Growth Capital Limited, Cell Genesys) and a disease-focused foundation (Michael J. Fox Foundation), and its strategic leadership has been anchored by co-founder and Chairman Stephen Sherwin.
Ceregene's revenue model, to the extent one can be inferred, is consistent with a pre-commercial clinical-stage biotech: no product revenue, no disclosed pricing model, and no commercial customers. Capital has come from periodic equity financings and a targeted foundation grant. Notably, no funding activity, product launches, or operational updates have been disclosed in the input data since the November 2010 Michael J. Fox Foundation round, and the company's public website is currently non-functional, returning only a loading page — suggesting either a prolonged period of low operational visibility or an effectively dormant operating posture.
Ceregene firmographics
Firmographics- Name
- Ceregene
- Website
- https://ceregene.com
- Company type
- Private
- Founded year
- 2000
- Headcount range
- 51–100 employees
- Short description
- Ceregene is a privately held San Diego-based biotechnology company founded in 2000 that develops therapies for neurodegenerative disorders by delivering nervous system growth factors to the nervous system.
- Ownership category
- akta.pro rank
Ceregene industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Neurology/CNS Gene Therapies (HLAAACAH)
Keywords
Where Ceregene is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Ceregene business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Ceregene product offering
Product offeringCore offering
Ceregene is a biotechnology company developing treatments for neurodegenerative disorders by delivering nervous system growth factors (neurotrophic factors) to the central nervous system using gene-therapy-based delivery. Its work is focused on disease-modifying approaches for conditions such as Parkinson's disease and Alzheimer's disease.
Differentiator
Problem solved
Functional benefit
Companies that use Ceregene
Customer profileIdeal customer profiles1 record
Ceregene technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Ceregene partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
Ceregene competitors and assessment
Company assessmentDirect peers
- REGENXBIO: Developer of AAV gene therapy platforms with active CNS pipeline including neurodegenerative disease programs — comparable through shared AAV technology base.
- GenSight Biologics: Gene therapy company focused on CNS and ophthalmologic neurodegenerative indications using AAV delivery — overlapping modality and target biology with Ceregene.
- Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments for severe neurological diseases including Parkinson's and ALS — the closest direct comparator to Ceregene's AAV-CNS growth factor approach.
- MeiraGTx: Clinical-stage gene therapy company with CNS and neurodegenerative programs using AAV vectors, directly comparable in modality and indication scope.
- Oxford BioMedica: Gene therapy developer with lentiviral and AAV capabilities targeting CNS and ocular neurodegenerative diseases — a directly comparable modality-and-indication peer.
- Axovant Gene Therapies (now Lexeo Therapeutics assets): Focused on gene therapies for CNS disorders including Parkinson's and dementia, sharing Ceregene's AAV-delivery modality and neurodegenerative target space.
Broad incumbents
- Sarepta Therapeutics: Established commercial-stage gene therapy company whose AAV-based neuromuscular programs share Ceregene's AAV platform and CNS-adjacent therapeutic strategy.
- Sangamo Therapeutics: Broader genomic medicine company with AAV and other gene therapy programs including neurological indications; comparable as a diversified gene therapy peer with CNS exposure.
- Pfizer (Gene Therapy / Rare Disease unit): Large pharma with an active AAV gene therapy franchise acquired from AveXis; a broad incumbent competing for the same CNS and rare neurological disease opportunities.
Emerging players
- Ionis Pharmaceuticals: Antisense-based neurology company with programs in Huntington's, ALS, and other neurodegenerative disorders — a comparable CNS-focused therapeutics peer using a different modality.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Ceregene social profiles
Digital presenceCeregene financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ceregene leadership team
Management profileNumber of profiles
Profiles1 record
Ceregene funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ceregene M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ceregene
What does Ceregene do?
Ceregene is a biotechnology company developing treatments for neurodegenerative disorders by delivering nervous system growth factors (neurotrophic factors) to the central nervous system using gene-therapy-based delivery. Its work is focused on disease-modifying approaches for conditions such as Parkinson's disease and Alzheimer's disease.
When was Ceregene founded?
Ceregene was founded in 2000. It employs 51 to 100 people.
Where is Ceregene based?
Ceregene is headquartered in San Diego, United States, in the North America region.
Who are Ceregene's main competitors?
Direct peers on record are REGENXBIO, GenSight Biologics, Voyager Therapeutics, MeiraGTx, Oxford BioMedica and Axovant Gene Therapies (now Lexeo Therapeutics assets). Broad incumbents are Sarepta Therapeutics, Sangamo Therapeutics and Pfizer (Gene Therapy / Rare Disease unit). Ionis Pharmaceuticals is listed as an emerging player.
Does Ceregene have an API?
No public API is recorded for Ceregene.
What industry is Ceregene in?
Ceregene's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 325414 and its SIC code is 2836.